OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
SK bioscience, a South Korean pharmaceutical firm, announced on Thursday, March 21, that it has exported its influenza vaccine to Thailand. The company developed a cell-cultured influenza vaccine, and after securing the required approvals and permits, it started exporting its Sky Cellflu to the country.
First Batch of Deliveries
According to The Korea Herald, SK Bioscience has already completed the first delivery, which consists of 440,000 doses of the Sky Cellflu vaccine. The products were handed over to its local partner, Biogenetech.
The Korean pharmaceutical company expects to receive more orders and expand its sales once the new influenza vaccine is distributed in Thailand. The deal also marks SK Bioscience's expansion in the Southeast Asian market and entry into the Southern space.
Timely Arrival of the Flu Vaccines
Korea IT Times reported that Thailand has been affected by flu strains, and vaccination is being sought to prevent infections. SK bioscience's Sky Cellflu was also approved by the World Health Organization (WHO) for use in the country.
Moreover, this export is expected to become an excellent example of proper vaccination to combat influenza. Meanwhile, Sky Cellflu already secured proper licenses for distribution in 12 countries, including Malaysia, Thailand, Chile, Singapore, Mongolia, and Pakistan.
World's First Cell Culture-Based Flu Vaccine
SK bioscience's SKYCellflu is said to be the first cell culture-based influenza vaccine in the world. It obtained WHO Pre-qualification (PQ) certification for safe usage and dissemination worldwide.
"The export of SKYCellflu to Thailand serves as a stepping-stone for entering the Southeast Asian and Southern Hemisphere markets and expanding into the global market," SK bioscience's chief executive officer, Ahn Jae Yong, said in a press release. "In addition to diversifying our existing product markets, we are committed to developing vaccines with blockbuster potential, such as our next-generation pneumococcal conjugate vaccine candidate, which is expected to enter phase III clinical trials this year."
Photo by: SK Bioscience Press Release
